Aetna considers that the prophylactic use of the dynamic splint is experimental and in the treatment of chronic contractures (no significant change in movement for a period of 4 months) and joint stiffness due to joint trauma, fractures, burns, head and spinal cord injuries, rheumatoid arthritis, multiple sclerosis, muscular dystrophy or cerebral palsy due to insufficient evidence in the peer-reviewed literature. However, if surgery is performed for a “chronic” condition, the use of a dynamic splint system may be considered medically necessary if the member meets the above selection criteria. If there is no significant improvement after four (4) months of use, dynamic devices (LLPS) for the toe, knee, elbow, wrist or finger will in no way be considered medically necessary, including, but not limited to, people who cannot benefit from standard physiotherapy modalities due to an inability to exercise. Aetna considers patient-operated serial stretching devices (PASS) (e.g. B, ERMI knee/ankle flexor, ERMI shoulder flexor, ERMI elbow extender, ERMI knee extender, ERMI MPJ extension cord, JAS EZ (ankles, elbows, fingers, knee extension, knee flexion, pronation/supination, shoulder, toe and wrist) and knee extension devices (e.B. Elite seat) as experimental and in the test, as the effectiveness of these devices is not sufficiently proven. Foot loss usually refers to the weakness or contracture of the muscles around the ankle joint. It can come from many neuromuscular diseases. In a Cochrane review, Sackley and colleagues (2009) conducted a systematic review of randomised trials to treat foot drops due to neuromuscular disease. Randomised and quasi-randomised trials of physical, orthotic and surgical treatments for foot falls resulting from diseases of the lower motor neuron or muscle and associated contractures were included. People with primary joint disease were excluded.
Interventions included a wait-and-see approach, physiotherapy, orthotics, surgery and pharmacological therapy. The primary outcome was quantified walking ability, while secondary endpoint measures included range of motion (ROM), dorsiflexory torque and strength, measures of activity and involvement, quality of life and side effects. Methodological quality was assessed by 2 authors based on van Tulder`s criteria. Four studies involving a total of 152 participants were included in the review. The heterogeneity of the studies prevented a pooling of data. Early surgery had no significant effect on walking speed in a study of 20 children with Duchenne muscular dystrophy. Both groups worsened during the 12-month follow-up. After 1 year, the mean difference (MD) in walking time of 28 feet was 0.00 seconds (95% confidence interval [CI]: -0.83 to 0.83) and md of 150-foot walking time was -2.88 seconds, favouring the control group (95% CI: -8.18 to 2.42). The nocturnal ankle splint had no significant effect on muscle strength or ROM around the ankle in a study involving 26 participants with Charcot-Marie-Tooth disease. Improvements were observed in the rail and control groups. In a study of 26 participants with Charcot-Marie-Tooth disease and 28 participants with myotonic dystrophy, 24 weeks of strength training significantly improved the time cycle by 6 meters in the Charcot-Marie-Tooth group compared to the control group (MD 0.70 second, promotes strength training, 95% CI: 0.23 to 1.17), but not in the myotone dystrophy group (MD -0.20 seconds, favouring the control group, 95% CI: -0.79 to 0.39).
No significant difference was observed for the 50-metre time trial in the Charcot-Marie-Tooth disease group (MD 1.90 seconds, favouring the exercise group, 95% CI -0.29 to 4.09) or the myotonic dystrophy group (MD -0.80 seconds, in favour of the control group, 95% CI -5.29 to 3.69). In a study of 65 participants with facioscapulohumeral muscular dystrophy, 26 weeks of strength training had no significant effect on ankle strength. After 1 year, the mean difference in maximum voluntary isometric contraction was -0.43 kg in favour of the control group (95% CI: -2.49 to 1.63) and the mean difference in dynamic strength was 0.44 kg, favouring the training group (95% CI: -0.89 to 1.77). The authors concluded that only 1 study involving people with Charcot-Marie-Tooth disease showed a statistically significant positive effect of strength training. No effect of strength training was found in people with myotonic dystrophy or facioscapulohumeral muscular dystrophy. Surgery had no significant effect in children with Duchenne muscular dystrophy and night ankle splint had no significant effect in people with Charcot-Marie-Tooth disease. They explained that more evidence is needed, which is generated by methodologically sound studies. The shoulder flexionator (ERMI Shoulder Flexionater) is designed to isolate and treat the decrease in glenohumeral abduction and external rotation. The device is designed to meet the needs of patients with excess scar tissue.
This customizable device includes pads arranged biomechanically and anatomically to focus the treatment on the glenohumeral joint without straining the other joints of the shoulder. Once adjusted, the shoulder flexor can be used by the patient at home without help to perform stretching exercises in series, alternately stretching and relaxing the scar tissue that surrounds the glenohumeral joint. The unit has 3 sections, the main frame, the arm unit and the pump unit.. .